Previous Close | 0.7788 |
1-Year Change | 39.07% |
6-Months Change | -33.44% |
3-Months Change | -43.97% |
Moving Avg (50d) | 0.9763 |
Moving Avg (200d) | 1.243 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 143.7M |
Beta (3-Years) | 1.7 |
Revenue Growth (ttm) | 5.53% |
Net Profit Margin (ttm) | -180.7% |
Return On Assets (ttm) | -54.65% |
EPS (ttm) | -0.84 |
PE Ratio (ttm) | -0.93 |
Dividend Yield | % |
Asset Description: | Nektar Therapeutics |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2025-01-24 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
0.794 | 0.818 | 0.833 | 0.857 | 0.896 | 0.935 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.